Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The degree of intactness of human cognitive functioning for a given individual spans a wide spectrum, ranging from normal to severely demented. The differential diagnosis for the causes of impairment along that spectrum is also wide, and often difficult to distinguish clinically, which has led to an increasing role for neuroimaging tools in that evaluation. The most frequent causes of dementia are neurodegenerative disorders, Alzheimer's disease being the most prevalent among them, and they produce significant alterations in brain metabolism with devastating neuropathologic, economic, social and clinical consequences. These alterations are detectable through positron emission tomography (PET), even in their earliest stages. The most commonly performed PET studies of the brain are carried out with [18F]fluorodeoxyglucose (FDG) as the imaged radiopharmaceutical. Such scans have demonstrated diagnostic and prognostic utility in evaluating patients with cognitive impairment, and in distinguishing among primary neurodegenerative disorders and other etiologies for cognitive decline. In addition to focusing upon the effects on cerebral metabolism examined with FDG PET, some other changes occurring in the brains of cognitively impaired patients assessable with other radiotracers will be considered. As preventive and disease-modifying treatments are developed, early detection of accurately diagnosed disease processes facilitated by the use of PET has the potential to substantially impact upon the enormous human toll exacted by these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Self-citationReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Self-citation
Cited by
Brain fuel metabolism, aging, and Alzheimer’s disease
Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., et al. (2011) · Nutrition · doi:10.1016/j.nut.2010.07.021 · Cited by 614
Bohnen, N. I., Djang, D. S. W., Herholz, K., Anzai, Y., & Minoshima, S. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096578 · Cited by 286
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia
Cerami, C., Della Rosa, P. A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S. F., & Perani, D. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.12.004 · Cited by 127
Yamane, T., Ikari, Y., Nishio, T., Ishii, K., Ishii, K., Kato, T., Ito, K., Silverman, D. H. S., Senda, M., Asada, T., et al. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3665 · Cited by 48
“The AD pattern in (18)F-FDG-PET is usually seen in the early stage of AD and is expected to predict the onset of AD.(1,12) Because most of the subjects who are clinically diagnosed as having AD may have had an established AD pattern in (18)F-FDG-PET, it is reasonable for these results that AD showed the highest concor…”
BackgroundCha, D., Michele, F., Soczynska, J., Woldeyohannes, H., Kaidanovich-Beilin, O., Carvalho, A., Malhi, G., Patel, H., Sim, K., Brietzke, E., et al. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130205024 · Cited by 18
Metadata
- Authors
- Silverman, D. H. S., Mosconi, L., Ercoli, L., Chen, W., & Small, G. W.
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 38
- Issue
- 4
- Pages
- 251-261
- ISSN
- 0001-2998 (ISSN-L)
- OpenAlex
- W2115104100
- Cited by
- 55
- References
- 22
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction. https://app.cochat.ai/papers/10.1053/j.semnuclmed.2008.02.006
- The paper
- Silverman, D. H. S., Mosconi, L., Ercoli, L., Chen, W., & Small, G. W. (2008). Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction. Seminars in Nuclear Medicine. https://doi.org/10.1053/j.semnuclmed.2008.02.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.